Angle Chemours is being valued at 7x forward earnings after a post-Q2 washout, versus a chemical-peer norm near 13x.
Daily MACD histogram at 0.18 with price above the signal line, stochastics at %K 77 and %D 73, and Bollinger %B at 0.55 point to short-term recovery momentum even as price sits 0.99% below the EMA20 within a strong downtrend. Weekly MACD histogram at -0.80 is turning higher while RSI holds near 40 with price still below the weekly SMA50, suggesting longer-term pressure may be easing without a full trend reversal yet. Rising OBV on sub-average volume fits bargain-hunting after the Q2 washout and supports the discounted-multiple thesis, though lower highs and the DMI bearish cross with ADX 25.6 argue for patient confirmation.
Triangulation
Indicators as of Aug 28, 2026 3:00 PM PT
| Trend | CAUTION | EMA20<SMA50<SMA200 · ADX 25.6 strong · -2.2% vs EMA20 · close<EMA20 · -DI > +DI |
| Momentum | HOLD | RSI 44.4 · RSIw 39.2 · hist 0.17 · MACD>signal |
| Stochastics | HOLD | %K/77 · %D/73 |
| Bollinger | HOLD | %B 0.48 · BW 19.2% · ATR 5.2% |
| Weekly | WATCHING | RSIw 39.2 · RSI<RSI-SMA · hist -0.81 · hist rising · close<SMA50 |
| Price action | WATCHING | 20d 41% · 52w 30% · lower highs (3) |
| Volume | HOLD | 0.43x avg · OBV ↑ |
| Position | HOLD | PnL +5.51% · peak +10.21% · dd -2.03% · 14d held |
